Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 283

The DOI matches its Crossref record.

PLX4032 in metastatic colorectal cancer patients with mutant BRAF tumors.

Kopetz, S., Desai, J., Chan, E., Hecht, J. R., O'Dwyer, P. J., Lee, R. J., Nolop, K. B., Saltz, L.·2010·Journal of Clinical Oncology

Abstract

3534 Background: The BRAF activating mutation is present in up to 10% of metastatic colorectal carcinomas (mCRC) and is associated with unique clinical and pathologic features with a very poor prognosis. PLX4032 (RG7204) is an oral inhibitor of the mutant BRAF kinase, with pronounced activity in BRAF-mutant melanoma patients (pts). Methods: In this phase I study, we treated an extension cohort of mCRC pts whose tumors were positive for mutant BRAF with PLX4032 at the previously determined maximum tolerated dose of 960 mg BID. The BRAF mutation was centrally confirmed by Taqman PCR. Efficacy was evaluated by RECIST every 8 weeks. Results: 21 mCRC pts were enrolled, with a median age of 65 and ECOG performance status of 0 (35%) or 1 (65%). All but one had received prior therapy for metastatic disease. PLX4032 PK values were ∼20% lower than than those previously observed for melanoma. 19 pts were evaluable for response, with 1 confirmed partial response and 4 minor responses (≥ 10% shrinkage). 5 pts showed a mixed response pattern (i.e., with both regressing and progressing lesions). 2 of the 3 pts who underwent repeat FDG-PET imaging achieved a metabolic response, which was concordant with RECIST changes. Median progression-free survival was 3.7 months, with 2 pts still on study. PLX4032 was generally well tolerated. Three pts had dose limiting toxicities of G3 rash and G3 nausea. Other G3 or G4 drug-attributable adverse events in all cycles were seen in 6 pts, and included fatigue, diarrhea, neutropenia, elevated alkaline phosphatase, hyponatremia, hypokalemia, and hyperbilirubinemia. Five pts developed cutaneous squamous cell carcinomas consistent with keratoacanthomas, which were managed by local excision. Conclusions: The clinical activity seen with PLX4032 in previously treated mCRC pts with V600E BRAF mutations is more modest than had been seen in melanoma, but this activity does confirm mutant BRAF as a therapeutic target in this disease. The biology of BRAF activation in pts with CRC is clearly more heterogenous than in melanoma, especially as evidenced in those pts with a mixed response. Subsequent studies are planned to evaluate PLX4032 in combination regimens in an attempt to improve efficacy in this poor prognosis subset of mCRC pts. Author Disclosure Employment or Leadership Position Consultant or Advisory Role Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Plexxikon, Roche Roche Plexxikon, Roche Plexxikon, Roche

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1200/jco.2010.28.15_suppl.3534

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 283

Metadata

Authors
Kopetz, S., Desai, J., Chan, E., Hecht, J. R., O'Dwyer, P. J., Lee, R. J., Nolop, K. B., & Saltz, L.
Venue
Journal of Clinical Oncology
Published
2010-05-20
Volume
28
Issue
15_suppl
Pages
3534-3534
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
OpenAlex
W1888056807
Cited by
283
References
0
Type
conference abstract
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: PLX4032 in metastatic colorectal cancer patients with mutant BRAF tumors. https://app.cochat.ai/papers/10.1200/jco.2010.28.15_suppl.3534
The paper
Kopetz, S., Desai, J., Chan, E., Hecht, J. R., O'Dwyer, P. J., Lee, R. J., Nolop, K. B., & Saltz, L. (2010). PLX4032 in metastatic colorectal cancer patients with mutant BRAF tumors. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2010.28.15_suppl.3534

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.